公司資料
Black Diamond Therapeutics 股價、新聞與催化劑
- 股票代碼:
- BDTX
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
2.05 USD (+1.49%)
收盤價
最後更新: 2026年8月17日
125M USD
市值
股價為何變動
As of Aug 17, 2026, BDTX closed up 1.49% at $2.05. No new same-company headline was identified in the current news window.
公司概覽
Mutation-Family Precision Oncology
Black Diamond Therapeutics develops MasterKey therapies designed to inhibit families of oncogenic mutations with a single small molecule.
Silevertinib
Silevertinib is a brain-penetrant kinase inhibitor targeting canonical and noncanonical EGFR mutations, including alterations that are difficult to address with mutation-specific drugs.
Frontline Lung Cancer
The Phase 2 non-small cell lung cancer program is evaluating response durability, progression-free survival and dose selection in patients with newly diagnosed EGFR-mutated disease.
Glioblastoma
A separate Phase 2 study evaluates silevertinib in newly diagnosed EGFRvIII-positive glioblastoma, using the candidate's brain penetration to address a distinct EGFR-driven tumor.
未來催化劑
- Phase 2 frontline EGFR-mutated NSCLC data, including preliminary duration-of-response and progression-free-survival results, at ASCO 2026.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。